# Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus

> **NCT06946485** · EARLY_PHASE1 · RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 15 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)

## Interventions

- **BIOLOGICAL:** Universal anti-CD70 CAR-T (CHT101)

## Key facts

- **NCT ID:** NCT06946485
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06946485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06946485, "Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06946485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*